NOVEL BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

• Main Authors: TORU IZUCHI, TOSHIYUKI MIYAZAWA, SATOKO HARADA, NOBUYOSHI KASUGAI, IZUMI GOTOH, YASUSHI OHSAWA, YUKA KUNO, YUKIYASU ASANO, HIROKI FUJIEDA, KATSUNORI KITAMOTO, YURIE YAMADA, MORIO OKABE, KEITA SAKAI, NAOKI TAKAHASHI, DAISUKE KURUMAZUKA, HIROKI NAGANO, MITSUAKI TAKEUCHI, HIROYO KATAOKA
• Format: Patent
• Language: Chinese; English
• Published: 11.03.2016
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

An object of the present invention is to provide a compound having a V2 receptor agonistic activity. Provided is a pharmaceutical composition which contains, as an active ingredient, a compound represented by the general formula (I) described below: [wherein R 1 is the formula described below: (wherein A is a lower alkylene group which may be substituted with a lower alkyl group, or the like; R 6 is a hydrogen atom, or the like; R 7 is a hydroxyl group, an aromatic heterocyclic group which may be substituted with a lower alkyl group, a carbamoyl group, or the like) ; R 2 is a hydrogen atom or a lower alkyl group; R 3 is a lower alkyl group which may be substituted with 1 to 3 fluorine atoms, or a halogen atom; R 4 is a five-membered aromatic monocyclic heterocyclic group, a five-membered non-aromatic monocyclic heterocyclic group, or the like, (provided that each of these heterocyclic groups contains at least one nitrogen atom and may be substituted with a lower alkyl group) ; and R 5 is a lower alkyl group, a halogen atom, or the like], or a pharmacologically acceptable salt thereof.